SCHEMBL1640596

SCHEMBL1640596

O=C(O)CNC(=O)c1c(O)c(C(=O)NC2CCCCC2)c(O)n(Cc2ccccc2Cl)c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 4/20 0.57
CNR1 P21554 1/20 0.50
CNR2 P34972 1/20 0.50
TSHR P16473 3/20 0.47
ALDH1A1 P00352 3/20 0.47
ALOX15 P16050 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
EGLN1 Q9GZT9 2/20 0.46
POLB P06746 1/20 0.45
TP53 P04637 1/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
GAA P10253 1/20 0.44
PPARG P37231 1/20 0.44
NCOA2 Q15596 1/20 0.44
EGLN2 Q96KS0 1/20 0.44
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL1641819 0.99 EGLN3 (0.56) EGLN3CNR1CNR2TSHRALDH1A1
SCHEMBL1641922 0.99 EGLN3 (0.58) EGLN3CNR1CNR2TSHRALDH1A1
SCHEMBL1642182 0.95 EGLN3 (0.60) EGLN3CNR1CNR2EGLN1POLB
SCHEMBL12727372 0.89 EGLN3 (0.51) EGLN3CNR1CNR2ALDH1A1EGLN1
SCHEMBL1641891 0.89 EGLN3 (0.55) EGLN3CNR1CNR2EGLN1POLB
SCHEMBL1640582 0.89 EGLN3 (0.55) EGLN3CNR1CNR2EGLN1NPC1
SCHEMBL1641149 0.86 EGLN3 (0.52) EGLN3CNR1CNR2ALDH1A1KDM4E
SCHEMBL1641907 0.85 EGLN3 (0.56) EGLN3CNR1CNR2EGLN1EGLN2
SCHEMBL1640347 0.85 EGLN3 (0.53) EGLN3CNR1CNR2EGLN1NPC1
SCHEMBL12727318 0.85 EGLN3 (0.74) EGLN3EGLN1TP53NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US claimed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP claimed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO claimed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN3 3/4885CNR1 2636/4885CNR2 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.